ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0486

Identifying Serum Metabolomic Markers Associated with Psoriasis Skin Disease Activity

Hani Choksi1, Sheng Han Li2, Nikita Looby2, Max Kotlyar3, Vathany Kulasingam4, Igor Jurisica5 and Vinod Chandran6, 1Schroeder Arthritis Institute, Krembil Research Institute, Krembil Research Institute, Toronto, ON, Canada, 2Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, 3Osteoarthritis Research Program, Division of Orthopaedic Surgery, Schroeder Arthritis Institute and Data Science Discovery Centre for Chronic diseases, Krembil Research Institute, Toronto, ON, Canada, 4Department of Laboratory Medicine and Pathobiology, University of Toronto and Division of Clinical Biochemistry, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada, 5Schroeder Arthritis Institute, Krembil Research Institute and Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, 6Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada

Meeting: ACR Convergence 2023

Keywords: Inflammation, metabolomics, Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 12, 2023

Title: (0483–0509) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: PsA

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Psoriasis is a chronic, immune-mediated inflammatory skin disease that affects over 2.5% of the global population. Approximately 25% of psoriasis patients also have a form of inflammatory arthritis called psoriatic arthritis (PsA). Current methods for evaluating skin disease activity, like Psoriasis Area and Severity Index (PASI), are subjective and prone to intra- and inter-rater variability. A metabolomics-based approach can elucidate psoriatic disease pathogenesis and provide potential objective biomarkers. Therefore, we aimed to use solid phase microextraction (SPME) with liquid chromatography coupled with mass spectrometry (LC-MS) with the hypothesis that serum metabolites are associated with skin disease activity.

Methods: Serum samples from PsA patients (n=151, summary of demographics and disease characteristics shown in Table 1) with active skin disease and a range of PASI scores were selected. Patients were classified into 3 groups of psoriasis activity based on PASI- low (PASI 1-4.8) n=56, moderate (PASI 5-9.8) n=45, and High (PASI 10.1-54.6) n=40. SPME devices were prepared in-house and used to conduct the sample preparation, followed by positive and negative ion mode data acquisition via an untargeted approach using LC-MS. Associations between the levels of each metabolite and PASI scores was evaluated using 8 Machine learning (ML) models including support vector machine (SVM), random forest, and Naïve Bayes (NB) with varied feature sizes of 1-80. These models were summarised using Area Under Receiver Operator Characteristic curves (AUROC) for performance. Statistically significant metabolite features were tentatively identified.

Results: ML models were able to distinguish between low and high PsA severity with Area Under Curve (AUC) score as low as 0.745 for 10 features, and as high as 0.813 for 40 features. Trends were similar for other disease activity comparisons. A SVM model with 10 features were able to predict between low and high severity PsA with AUC = 0.862, and p-value < 0.05. Table 2 provides a summary of the results of the analyses. The features of interest used in best performing models were associated with dysregulation of fatty acid metabolism when predicting between low PASI versus moderate or high PASI. Some metabolites tentatively identified include eicosanoids with anti- or pro-inflammatory properties, like 12-Hydroxyeicosatetraenoic acid, which was previously implicated in joint disease activity in PsA. Other tentatively identified features belong to classes such as bile acid metabolites, oxidized phospholipids, N-acrylamide, and long-chain fatty acids.

Conclusion: An untargeted metabolomics approach was employed to analyze potential differences in serum metabolome of PsA patients of varying skin disease activity. Confirmation and validation of the tentatively identified circulating metabolites should be conducted to reveal potential biomarkers of PsA disease activity.

Supporting image 1

Table 1: Summary of disease characteristics and patient demographics

Supporting image 2

Table 2: Top 10 Tentatively Identified Metabolites for Low vs High PASI Disease Activity


Disclosures: H. Choksi: None; S. Li: None; N. Looby: None; M. Kotlyar: None; V. Kulasingam: None; I. Jurisica: None; V. Chandran: AbbVie, 1, 5, 6, Amgen, 1, 5, 6, AstraZeneca, 3, Bristol-Myers Squibb (BMS), 1, 6, Eli Lilly, 1, 5, 6, Janssen, 1, 6, Novartis, 1, 1, 6, UCB, 1, 2.

To cite this abstract in AMA style:

Choksi H, Li S, Looby N, Kotlyar M, Kulasingam V, Jurisica I, Chandran V. Identifying Serum Metabolomic Markers Associated with Psoriasis Skin Disease Activity [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/identifying-serum-metabolomic-markers-associated-with-psoriasis-skin-disease-activity/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identifying-serum-metabolomic-markers-associated-with-psoriasis-skin-disease-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology